These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1477 related articles for article (PubMed ID: 28254435)

  • 1. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
    Liu H; Shen J; Lu K
    Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
    Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGF-β1-Induced SOX18 Elevation Promotes Hepatocellular Carcinoma Progression and Metastasis Through Transcriptionally Upregulating PD-L1 and CXCL12.
    Chen J; Feng W; Sun M; Huang W; Wang G; Chen X; Yin Y; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
    Gastroenterology; 2024 Jul; 167(2):264-280. PubMed ID: 38417530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions between interleukin-6 and myeloid-derived suppressor cells drive the chemoresistant phenotype of hepatocellular cancer.
    Xu M; Zhao Z; Song J; Lan X; Lu S; Chen M; Wang Z; Chen W; Fan X; Wu F; Chen L; Tu J; Ji J
    Exp Cell Res; 2017 Feb; 351(2):142-149. PubMed ID: 28109867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.
    Kim KJ; Kim JH; Lee SJ; Lee EJ; Shin EC; Seong J
    Oncotarget; 2017 Jun; 8(25):41242-41255. PubMed ID: 28465485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity.
    Tao Z; Ruan H; Sun L; Kuang D; Song Y; Wang Q; Wang T; Hao Y; Chen K
    Cancer Immunol Res; 2019 Jul; 7(7):1135-1147. PubMed ID: 31113805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-associated fibroblasts-derived exosomal ZNF250 promotes the proliferation, migration, invasion, and immune escape of hepatocellular carcinoma cells by transcriptionally activating PD-L1.
    Feng H; Liu J; Jia H; Bu X; Yang W; Su P
    J Biochem Mol Toxicol; 2024 Sep; 38(9):e23778. PubMed ID: 39252517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
    Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors.
    Huang T; Li F; Cheng X; Wang J; Zhang W; Zhang B; Tang Y; Li Q; Zhou C; Tu S
    Front Immunol; 2021; 12():619209. PubMed ID: 33790893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-1β-Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up-regulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1.
    He Q; Liu M; Huang W; Chen X; Zhang B; Zhang T; Wang Y; Liu D; Xie M; Ji X; Sun M; Tian D; Xia L
    Hepatology; 2021 Dec; 74(6):3174-3193. PubMed ID: 34288020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint therapy in liver cancer.
    Xu F; Jin T; Zhu Y; Dai C
    J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The polymorphism rs975484 in the protein arginine methyltransferase 1 gene modulates expression of immune checkpoint genes in hepatocellular carcinoma.
    Schonfeld M; Zhao J; Komatz A; Weinman SA; Tikhanovich I
    J Biol Chem; 2020 May; 295(20):7126-7137. PubMed ID: 32245889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
    Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
    Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of liver-targeted drugs on expression of immune-related proteins in hepatocellular carcinoma cells.
    Qiu MJ; He XX; Bi NR; Wang MM; Xiong ZF; Yang SL
    Clin Chim Acta; 2018 Oct; 485():103-105. PubMed ID: 29940148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.
    Ke MY; Xu T; Fang Y; Ye YP; Li ZJ; Ren FG; Lu SY; Zhang XF; Wu RQ; Lv Y; Dong J
    Cancer Lett; 2021 Aug; 513():14-25. PubMed ID: 33992711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 74.